Quick Answer
Pelthos Therapeutics Inc. reported Operating Income of -$32.43 million for fiscal year 2025.
Pelthos Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$32.43M | -328.3% |
| 2024 | -$7.57M | -10.3% |
| 2023 | -$6.86M | -196.0% |
| 2022 | -$2.32M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.36M | -649.7% | -375.5% |
| June 30, 2025 | -$3.23M | -83.1% | -76.1% |
| March 31, 2025 | -$1.83M | +5.2% | +10.5% |
| September 30, 2024 | -$2.05M | -58.6% | -16.2% |
| June 30, 2024 | -$1.76M | -127.0% | +8.8% |
| March 31, 2024 | -$1.93M | -111.5% | -49.7% |
| September 30, 2023 | -$1.29M | — | -66.2% |
| June 30, 2023 | -$777.2K | — | +15.0% |
- Pelthos Therapeutics Inc. showed a decrease of -328.3% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Pelthos Therapeutics Inc.’s operating income has declined by 1299.0% (from -$2.32 million to -$32.43 million).
- The most recent figure is from Pelthos Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: